These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

390 related articles for article (PubMed ID: 26629420)

  • 1. Angiogenesis inhibition as a therapeutic strategy in non-small cell lung cancer (NSCLC).
    Hall RD; Le TM; Haggstrom DE; Gentzler RD
    Transl Lung Cancer Res; 2015 Oct; 4(5):515-23. PubMed ID: 26629420
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies targeting vascular endothelial growth factor: current status and future challenges in cancer therapy.
    Hsu JY; Wakelee HA
    BioDrugs; 2009; 23(5):289-304. PubMed ID: 19754219
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Strategies targeting angiogenesis in advanced non-small cell lung cancer.
    Wang J; Chen J; Guo Y; Wang B; Chu H
    Oncotarget; 2017 Aug; 8(32):53854-53872. PubMed ID: 28881856
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic implication of vascular endothelial growth factor receptor-1 (VEGFR-1) targeting in cancer cells and tumor microenvironment by competitive and non-competitive inhibitors.
    Lacal PM; Graziani G
    Pharmacol Res; 2018 Oct; 136():97-107. PubMed ID: 30170190
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vascular endothelial growth factor is an autocrine growth factor, signaling through neuropilin-1 in non-small cell lung cancer.
    Barr MP; Gray SG; Gately K; Hams E; Fallon PG; Davies AM; Richard DJ; Pidgeon GP; O'Byrne KJ
    Mol Cancer; 2015 Feb; 14():45. PubMed ID: 25889301
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Neovasculature with Multitargeted Antiangiogenesis Tyrosine Kinase Inhibitors in Non-small Cell Lung Cancer.
    Skouras VS; Maragkos C; Grapsa D; Syrigos KN
    BioDrugs; 2016 Oct; 30(5):421-439. PubMed ID: 27670779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeted Therapy for NSCLC--A Double-edged Sword?
    Dempke WC
    Anticancer Res; 2015 May; 35(5):2503-12. PubMed ID: 25964523
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Exploring the Benefit/Risk Associated with Antiangiogenic Agents for the Treatment of Non-Small Cell Lung Cancer Patients.
    Kurzrock R; Stewart DJ
    Clin Cancer Res; 2017 Mar; 23(5):1137-1148. PubMed ID: 27940520
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting Angiogenesis in Cancer Therapy: Moving Beyond Vascular Endothelial Growth Factor.
    Zhao Y; Adjei AA
    Oncologist; 2015 Jun; 20(6):660-73. PubMed ID: 26001391
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Role of the Antiangiogenetic Ramucirumab in the Treatment of Advanced Non Small Cell Lung Cancer.
    Maione P; Sgambato A; Casaluce F; Sacco PC; Santabarbara G; Rossi A; Gridelli C
    Curr Med Chem; 2017; 24(1):3-13. PubMed ID: 27855622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer.
    Langer C; Soria JC
    Clin Lung Cancer; 2010 Mar; 11(2):82-90. PubMed ID: 20199973
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.
    Losanno T; Rossi A; Maione P; Napolitano A; Gridelli C
    Expert Opin Biol Ther; 2016 Jun; 16(6):747-58. PubMed ID: 26950292
    [TBL] [Abstract][Full Text] [Related]  

  • 13. New antiangiogenetic agents and non-small cell lung cancer.
    Gridelli C; Rossi A; Maione P
    Crit Rev Oncol Hematol; 2006 Oct; 60(1):76-86. PubMed ID: 16843002
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The emerging role of vascular endothelial growth factor receptor tyrosine kinase inhibitors.
    Langer CJ; Natale RB
    Semin Oncol; 2005 Dec; 32(6 Suppl 10):S23-9. PubMed ID: 16459176
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aspirin Affects Tumor Angiogenesis and Sensitizes Human Glioblastoma Endothelial Cells to Temozolomide, Bevacizumab, and Sunitinib, Impairing Vascular Endothelial Growth Factor-Related Signaling.
    Navone SE; Guarnaccia L; Cordiglieri C; Crisà FM; Caroli M; Locatelli M; Schisano L; Rampini P; Miozzo M; La Verde N; Riboni L; Campanella R; Marfia G
    World Neurosurg; 2018 Dec; 120():e380-e391. PubMed ID: 30144594
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Angiogenesis inhibitors and vascular disrupting agents in non-small cell lung cancer.
    Rossi A; Maione P; Ferrara ML; Sacco PC; Schettino C; Bareschino MA; Gridelli C
    Curr Med Chem; 2009; 16(30):3919-30. PubMed ID: 19747132
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging angiogenesis inhibitors for non-small cell lung cancer.
    Malapelle U; Rossi A
    Expert Opin Emerg Drugs; 2019 Jun; 24(2):71-81. PubMed ID: 31092048
    [No Abstract]   [Full Text] [Related]  

  • 18. Anti-Angiogenics: Their Value in Lung Cancer Therapy.
    Janning M; Loges S
    Oncol Res Treat; 2018; 41(4):172-180. PubMed ID: 29631257
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the VEGF pathway: antiangiogenic strategies in the treatment of non-small cell lung cancer.
    Aita M; Fasola G; Defferrari C; Brianti A; Bello MG; Follador A; Sinaccio G; Pronzato P; Grossi F
    Crit Rev Oncol Hematol; 2008 Dec; 68(3):183-96. PubMed ID: 18606548
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Beyond bevacizumab: antiangiogenic agents.
    Rogosin S; Sandler AB
    Clin Lung Cancer; 2012 Sep; 13(5):326-33. PubMed ID: 22297207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.